Goldman Sachs adds Gilead Sciences (GILD) to its Conviction Buy list, calling its acquisition...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Goldman Sachs adds Gilead Sciences (GILD) to its Conviction Buy list, calling its acquisition strategy "transformational." Analysts with the firm set a $46 price target on shares - hailing the mega-acquisition of Pharmasset (VRUS) as a move that changes the stock to a value story from a growth story.